Bomyntra (denosumab)
Numéro de dossier de l’APP:
23493
État des négociations:
En négociation
Indication(s):
• reducing the risk of developing skeletal-related events in patients with multiple myeloma and in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumors;
• treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severemorbidity; and
• treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate
• treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severemorbidity; and
• treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate
Promoteur/fabricant:
Fresenius Kabi Canada Ltd.
Numéro de projet de l’AMC:
Sans objet
Lettre d’entente de l’APP:
Conclusion du processus de négociation:
Sans objet